JAZZ Jazz Pharmaceuticals plc

+0.8  (+1%)
Previous Close 125.21
Open 125.71
Price To Book 2.51
Market Cap 7601123556
Shares 60,321,590
Volume 546,082
Short Ratio
Av. Daily Volume 674,405

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 enrollment to be completed 4Q 2018.
Cataplexy and Excessive Daytime Sleepiness in Narcolepsy
CRL received October 11, 2010.
Phase 2 enrollment initiation announced February 8, 2017.
Excessive Sleepiness in Parkinson's Disease
FDA Approval announced October 26, 2018.
Pediatric narcolepsy patients with cataplexy
Phase 3 data released March 20, 2017 - primary endpoints met.
Excessive sleepiness associated with obstructive sleep apnea
PDUFA date extended by three months to March 20, 2019.
Excessive sleepiness associated with narcolepsy
Phase 3 dosing initiation announced January 18, 2017.
VOD in high-risk patients following hematopoietic stem cell transplantation
Approval announced August 3, 2017.
Acute myeloid leukemia
Phase 2 commencement of enrollment announced February 23, 2018.
acute Graft-versus-Host-Disease (aGvHD)
Phase 3 commencement of enrolment announced November 29, 2018.
Idiopathic Hypersomnia

Latest News

  1. Mylan (MYL) to Report Q4 Earnings: What's in the Offing?
  2. New Research: Key Drivers of Growth for IPG Photonics, Keane Group, Jazz Pharmaceuticals, Tredegar, Carriage Services, and Surgery Partners — Factors of Influence, Major Initiatives and Sustained Production
  3. Jazz Pharmaceuticals Announces Appointment of Anne O'Riordan to its Board of Directors
  4. Jazz Pharmaceuticals to Report 2018 Fourth Quarter and Full Year Financial Results on February 26, 2019
  5. Factors to Know Ahead of Herbalife's (HLF) Q4 Earnings
  6. See what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
  7. Why Jazz (JAZZ) Could Beat Earnings Estimates Again
  8. What Investors Should Know About Jazz Pharmaceuticals plc’s (NASDAQ:JAZZ) Financial Strength
  9. Edited Transcript of JAZZ earnings conference call or presentation 7-Aug-18 8:30pm GMT
  10. 5 Biotech Stocks That Could Face M&A Next!
  11. At biotech's big event, a chance for execs to shape LGBTQ diversity on boards
  12. 3 Bargain Stocks You Can Buy Right Now
  13. Jazz Inks Deal with Codiak to Develop Exosome Therapeutics
  14. Jazz Pharmaceuticals and Codiak BioSciences Announce Strategic Collaboration to Research, Develop and Commercialize Engineered Exosomes to Create Therapies for Hard-to-Treat Cancers
  15. Should Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Be Your Next Stock Pick?
  16. 3 of the Cheapest Drug Stocks You Can Buy in 2019
  17. Jazz (JAZZ) Falls as Sleep Drug Gets Extended Review From FDA
  18. Pharma Stock Dives On Delayed Drug — Is The Reaction 'Outsized'?